News
Two countries. One shared diagnosis. Wildly different receipts at the pharmacy.
Across Europe in 2026, medical cannabis patients navigating prescription access are discovering that geography determines price as much as any clinical factor. A comparison of the UK and German medical cannabis markets — published by Business of Cannabis — illustrates just how unevenly the continent's medical frameworks have developed, even as more countries move toward some form of regulated access.
Germany: Volume, Variety, and a Changing Reimbursement Landscape
Germany remains the largest medical cannabis market in Europe by prescription volume. Following its 2017 legalisation of medical cannabis on prescription, the country built a framework through which patients could, in principle, access reimbursement through statutory health insurers. In practice, reimbursement approvals have been inconsistent — but the sheer scale of the German market has driven product variety and, over time, price competition among licensed producers.
The Business of Cannabis analysis notes that German pharmacy prices for dried flower products have shifted considerably as more suppliers entered the market, with some products now available at price points that would have seemed unlikely five years ago. The liberalisation of adult-use cannabis in Germany — which came into partial effect in April 2024 — has created additional complexity, as the boundary between adult-use and medical frameworks remains contested in both policy and practice.
The UK: A Private Market With Public Consequences
The United Kingdom legalised medical cannabis on prescription in November 2018, but access has remained almost entirely private. The National Health Service prescribes medical cannabis in only a narrow range of conditions; the vast majority of the estimated tens of thousands of UK medical cannabis patients pay out of pocket through private clinics.
That private structure shapes everything. UK patients report paying significantly more per gram for comparable products than their German counterparts — a gap that the Business of Cannabis analysis frames as a market-access problem rather than a product-quality issue. The UK market has seen consolidation among private cannabis clinics, and while competition has moderated some prices, the absence of public reimbursement keeps costs prohibitive for lower-income patients.
The result is a system that works reasonably well for patients who can afford a monthly subscription to a private clinic and a regular pharmacy spend — and poorly for everyone else.
What This Means Beyond the Channel
The UK-Germany comparison is not merely a bilateral curiosity. It reflects a structural tension running through every European country that has introduced medical cannabis access: who pays, and on what terms.
In Malta, medical cannabis has been available on prescription since 2018, predating the country's better-known adult-use reform under Chapter 628 of the Laws of Malta in 2021. Maltese patients access medical cannabis through the state health system in limited circumstances, though the pathway has historically been narrow. The Maltese medical framework is administered separately from the ARUC (Authority on the Responsible Use of Cannabis) — the regulator that oversees adult-use Cannabis Harm Reduction Associations (CHRAs) — and conflating the two frameworks remains a common source of confusion for consumers and, occasionally, in public reporting.
For Maltese patients, the practical questions mirror those facing UK consumers: how many conditions qualify, how accessible is a prescribing specialist, and does the cost land on the patient or the public purse? Those questions do not yet have complete public answers, and ARUC's mandate does not extend to the medical side.
Price as a Harm Reduction Issue
There is a harm reduction argument — one that tends to get lost in market-structure discussions — that pricing is not merely a consumer inconvenience. When medical cannabis is priced beyond what patients can afford, some will source cannabis outside regulated channels. That outcome serves no one: it removes product safety guarantees, leaves patients without clinical oversight, and undermines the core rationale for regulated access.
Germany's trajectory — more suppliers, more competition, gradually declining prices — suggests that scale and regulatory clarity can move markets in a patient-friendly direction. The UK's stasis around private-only access suggests the opposite. The divergence is worth watching closely, not because either model is perfect, but because the choice between them has consequences that fall hardest on the patients least able to absorb them.
For a continent still building its medical cannabis infrastructure, the lesson from London and Berlin may be simpler than the policy papers suggest: access that depends entirely on a patient's bank balance is not really access at all.
Sources:
Business of Cannabis, UK vs Germany – Medical Cannabis Products & Prices (2026 Update)
Featured image: Photo by cottonbro studio on Pexels
Members Discussion